Eli Lilly (LLY) has ended a three-day selloff after Goldman Sachs analyst Asad Haider upgraded the Indiana-based drugmaker to Buy from Neutral, citing an attractive entry point given its ...

Goldman Sachs analyst Asad Haider resumed coverage with a Buy rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target of $172.00. The company’s shares opened today ...

Goldman Sachs analyst Asad Haider assumed coverage of AbbVie (ABBV) with a Neutral rating and $194 price target The company’s “strong” growth for “commercial powerhouses” Skyrizi and ...

Eli Lilly (LLY) has ended a three-day selloff after Goldman Sachs analyst Asad Haider upgraded the Indiana-based drugmaker to Buy from Neutral, citing an attractive entry point given its ...